Needham analyst Alan Carr assigned a Buy rating to SCYNEXIS (SCYX) today and set a price target of $50.00. The company’s shares closed last Friday at $4.90, close to its 52-week low of $4.20.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.5% and a 43.0% success rate. Carr covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Lexicon Pharmaceuticals, and Crispr Therapeutics AG.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SCYNEXIS with a $36.67 average price target, implying a 673.6% upside from current levels. In a report released today, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $25.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.40 and a one-year low of $4.20. Currently, SCYNEXIS has an average volume of 68.46K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
